Alterity Therapeutics (ATHE) Invested Capital (2011 - 2025)

Alterity Therapeutics' Invested Capital history runs 13 years deep, the most recent figure standing at -$1.7 million for Q2 2025.

• In Q2 2025, Invested Capital rose 45.61% year-over-year to -$1.7 million; the TTM figure through Dec 2025 stood at -$5.0 million (up 13.01% YoY), while the FY2025 annual figure was -$1.7 million, up 45.61% from the prior year.
• Invested Capital for Q2 2025 stood at -$1.7 million, up from -$3.2 million in the prior quarter.
• The five-year high for Invested Capital was -$1.7 million in Q2 2025, with the low at -$3.7 million in Q2 2022.
• The 5-year median for Invested Capital is -$2.5 million (2023), against an average of -$2.6 million.
• The sharpest annual moves came in 2022 and 2025: Invested Capital plunged 89.21% in 2022, then jumped 45.61% in 2025.
• Alterity Therapeutics' Invested Capital stood at -$2.0 million in 2021, then slumped by 89.21% to -$3.7 million in 2022, then jumped by 33.41% to -$2.5 million in 2023, then retreated by 29.04% to -$3.2 million in 2024, then jumped by 45.61% to -$1.7 million in 2025.
• Business Quant data shows ATHE's Invested Capital at -$1.7 million in Q2 2025, -$3.2 million in Q2 2024, and -$2.5 million in Q2 2023.